Jasper Therapeutics Announces First Patient Dosed In A Phase 1 Trial Of Briquilimab In Lower-Risk Myelodysplastic Syndrome
Portfolio Pulse from Bill Haddad
Jasper Therapeutics has announced the dosing of the first patient in a Phase 1 trial of Briquilimab for lower-risk myelodysplastic syndrome. This marks a significant milestone for the company's clinical development program.
June 22, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jasper Therapeutics has dosed the first patient in a Phase 1 trial of Briquilimab, potentially leading to positive outcomes for the company's clinical development program.
The dosing of the first patient in the Phase 1 trial of Briquilimab is a significant milestone for Jasper Therapeutics. Positive results from the trial could lead to increased investor confidence and potential growth in the company's stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100